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法免疫昆明种小鼠，经过 31 天的免疫，获得鼠抗 CV-N 的多克隆抗体。采用间
接酶联免疫吸附（ELISA）方法，测得抗体效价超过 1：8000，蛋白印迹（Western 
blot）分析结果显示，该抗体能特异性地与 CV-N 抗原产生明显免疫亲和反应。


















本研究采用 pET原核表达系统克隆表达 CV-N，制备了鼠抗 CV-N多克隆抗















重组质粒 pET-(2F54E10)4。重组质粒 pET-（2F54E10）4转入 Gold code表达宿主
菌中，IPTG 诱导表达，SDS-PAGE 鉴定目的蛋白，凝胶电泳分析发现在预期外









































HIV-1 epitope peptide and Cyanovirin-N Express and 
bioactivity of Cyanovirin-N primary study 
Abstract 
The entry of HIV into host cells is mainly mediated by the fusion of the viral 
and cellular membranes, which involves the interactions of a series of 
biomacromolecules, such as gp120 and gp41, CD4 and CCR5. The deep 
understanding of the crystal structures, the surfactant details of their interaction, and 
the change of conformation during interaction of the macromolecules provides a new 
idea for the anti HIV drugs. This research consists of two parts. The first part is 
Cyanovirin-N Expression in E.coli and primary study of its bioactivity; the second 
part is Expression of HIV-1 Neutralizing Epitope Peptides. 
In the first part, Cyanovirin-N (CV-N) originally isolated (Boyd MR et al.) from 
an aqueous extract of the cyanobacterium, Nostoc elliposporum, is 11 KD natural 
polypeptide with potent human immunodeficiency virus (HIV)-inactivity. It has been 
proved to suppress a broad range of respiratory and enteric viruses. Cyanovirin-N can 
specifically combine with the membrane of the virus particles so as to prevent virus 
binding to antigen of the host cells. The unique character of Cyanovirin-N makes it a 
potential new lead for the design of drugs against AIDS.  
The nucleotide sequence of Cyanovirin-N was obtained by PCR. The expression 
plasmid pET-CVN was constructed by inserting the sequence of coding region of 
CV-N into pET-His vecter which contained T7 promoter. Recombinant expression 
plasmid pET-CVN was verified by restriction endonuclease analysis and PCR and 
sequencing, and then was transformed into E.coli BL21 (DE3). Expression of CV-N 
was induced by IPTG at 30℃ for 8 hours. The expressed fusion protein was analyzed 
by SDS-PAGE, and the results indicated that 12.7KD protein expressed particularly in 
transformants. Also the Cyanovirin-N was expressed in the form of insoluble 
inclusion body, and the expression amount of Cyanovirin-N is about 42.00% of total 
proteins. Cyanovirin-N was refolded by using dialysis method. The target protein was 














Cyanovirin-N was immune antigen. Rats were immunized and the polycolonal 
antibody to Cyanovirin-N was obtained. The titer of antibody was more than 1:8000 
by ELISA detection. Western blot analysis showed that the antibody can bind with 
Cyanovirin-N specifically. The prepared antibody against Cyanovirin-N has good 
specificity and reactivity and can be used to detect the expression products of 
transgenic which expressed Cyanovirin-N gene. Cyanovirin-N was tagged with FITC. 
The recombinant Cyanovirin-N can specifically bind to gp120 on the membrane of 
the HIV particles analyzed by ELISA and Western-blot. The results showed that the 
recombinant Cyanovirin-N had bioactivity. In vitro assays to determine the activity of 
CV-N against a variety of influenza virus produced results that could be strong effect 
on anti-influenza A/B virus. 
In this research, Cyanovirin-N was successfully cloned and expressed in E.coli, 
and obtained polycolonal antibody against Cyanovirin-N and Cyanovirin-N-FITC 
which was tagged with FITC. Construction of pET-CVN, Cyanovirin-N (CV-N) 
expressed plasmid, provided an efficient method to develop a broad-spectrum, cheap 
and facile genetic mutant medicine against AIDS, and prepared specific polycolonal 
antibody, which laid the foundation for study of its function. 
In the second part, Acquired Immunodeficiency Syndrome (AIDS) is a serious 
and worldwide health problem. In the past, passing immunity and vaccine-induced 
neutralizing antibodies (nAbs) responses against HIV were disappointing. However, 
recent data have shown surprising successes of anti-HIV nAbs. Epitope recognized by 
the protective monoclonal antibodies are an important determinants for protection and 
provide a rational basis for AIDS vaccine development. 
In this research, the nucleotide sequence of HIV-1 two neutralizing epitope 
peptide 2F54E10 (NEQELLELDKWASLWN-NWFDIT) was obtained by PCR. The 
tandem 2F5E410 gene of 4 repeats was concatenated by gene engineering method. 
The 4 repeats gene encoding 2F54E10 was cloned into pET-His vector, and then 
recombinant expression plasmid pET-(2F54E10)4 required was verified by restriction 














transformed into E.coli Gold code and induced at 37℃ with 0.5mM IPTG for 3 hours. 
The expressed fusion protein was analyzed by SDS-PAGE, and the result indicated 
12.0KD protein expressed particularly in transformants that was coherent with the 
aimed protein HIV-1 neutralizing antibody 2F54E10. The target protein was isolated 
and purified by gel extraction purification. The highly purified target protein was used 
to immune mice to prepare polyclonal antibodies. The titer of antibodies to 2F54E10 
was more than 1:12800 by ELISA detection. Western bolt analysis showed that the 
polyclonal antibodies could bind with natural gp41 specifically. 
In this study, the HIV-1 two neutralizing epitope peptide 2F54E10 was 
successfully expressed in the Ecoli. Gold code, and obtained polyclonal antibodies. 
It’s the first time to use gene engineering method to concatenat tandem 2F5E410 gene 
of 4 repeats to express HIV-1 neutralizing epitope peptide. We hope that the strong 
neutralizing antibody provide a rational basis for the anti-HIV-1 vaccine development. 
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图A-1 CV-N的一级结构 
          Fig.A-1 Primary DNA sequence of CV-N 
                 
图A-2 位于CV-N链内的2个二硫键示意图 


























体。在X-射线衍射中，主链原子的平均方差衍射仅为0.55 Å 。 
                                                                 
                                              
 
 
图 A-3 CV-N晶体空间结构示意图 
Fig. A-3 The crystal structure of CV-N 


















Fig.A-4 The solution structure of CV-N 



































抑制 HIV 病毒活性与天然 CV-N 的基本相同[14]。内部序列交换的 CV-N 突变体
（dsCV-N），功能域 A、B的核心部位进行交换而前三与最后三个氨基酸残基没
有交换，抑制 HIV 病毒融合作用远远低于天然 CV-N 的 [15]。环绕排序
（circularly-permuted）的 CV-N突变体（cpCV-N），其稳定性、抗病毒活性均低
于天然 CV-N的[16，17，18]。Laura[19] 等人研究 CV-N单体与二聚体的互变，结果表
明 CV-N抗病毒活性基本不会受到影响。2003年 Botos [10]等人对 CV-N及其突变
体的生物活性进行统计，见表 A-1。 
表 A-1 CV-N 及其突变体的生物活性 
Table.A-1 Summary of biological activity of CV-N and its mutants 
Protein Order of residues  EC50(nM) Refercen 
index 
Wide-typeCVN 1-101 0.9±0.4 33 
CVN-1 2-101 2.0±0.7 33 
CVN-2 3-101 8.3±4.0 33 
CVN-3 4-101 140.7±36.7 33 
F-CVN 1-101 3.6±1.4 33 
F-CVN 1-98 149.5±17.2 33 
F-CVN 1-93 inactive 33 
F-D1D1 1-50, 1-50 inactive 33 
F-D2D2 52-101,51-101 inactive 33 
F-D2D1 52-101,1-50 217.7±9.5 33 
F-C8S-C22S 1-101 inactive 33 
F-C58S-C73S 1-101 inactive 33 
  EC50(nM)  
Wide-typeCV-N 1-101 0.19 34 
A77T 1-101 0.22 34 
S52P 1-101 1.46 34 
cpCVN 1-3,54-98,48-53,4-47,99-101 1000×less potent than wt 39 
dsCVN 1-3,54-98,48-53,4-47,99-101 500×less potent than wt 38 
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